June 16, 2009 - MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, and the Karpov Institute of Physical Chemistry in Moscow, Russia, have agreed to study the feasibility of the Karpov Institute providing the company with a flexible, reliable and responsive medical-isotope supplier of molybdenum-99 (Mo-99) for the global nuclear medicine market.
MDS Nordion and the Karpov Institute have agreed to combine their respective expertise and resources to explore the development of a commercialization plan to address a portion of the need for a long-term supply of moly-99.
Together, MDS Nordion and the Karpov Institute have strong technical and operational expertise. MDS Nordion has substantial technical and marketing knowledge; the Karpov Institute brings substantial nuclear infrastructure and expertise in physics and reactor operations.
The Karpov Institute of Physical Chemistry is classified as a State Scientific Centre, which has been involved in basic and applied research in the area of physical chemistry for more than 90 years. Production of medical isotopes and radiopharmaceuticals using the capabilities of the WWR-c research reactor is one of the most important multidirectional activities currently developed at the institute. The Karpov Institute is the main supplier (90 percent) of Mo-99 and Tc-99m generators to the domestic Russian market. Our products are delivered weekly to more than 200 clinics throughout Russia.
For more information: www.mdsnordion.com